Insider Buying: Galectin Therapeutics Director Purchases 1,000 Shares of Stock (GALT)
Galectin Therapeutics (NASDAQ:GALT) Director Arthur Greenberg purchased 1,000 shares of the stock on the open market in a transaction dated Tuesday, August 19th. The stock was purchased at an average price of $4.56 per share, with a total value of $4,560.00. Following the completion of the acquisition, the director now directly owns 96,667 shares in the company, valued at approximately $440,802. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Galectin Therapeutics (NASDAQ:GALT) traded up 10.03% on Wednesday, hitting $5.0392. 654,237 shares of the company’s stock traded hands. Galectin Therapeutics has a 52 week low of $4.28 and a 52 week high of $19.11. The stock’s 50-day moving average is $9.66 and its 200-day moving average is $12.64. The company’s market cap is $111.1 million.
Galectin Therapeutics (NASDAQ:GALT) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.04. Analysts expect that Galectin Therapeutics will post $-1.03 EPS for the current fiscal year.
A number of analysts have recently weighed in on GALT shares. Analysts at Aegis downgraded shares of Galectin Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, August 1st. Separately, analysts at BMO Capital Markets reiterated a “positive” rating on shares of Galectin Therapeutics in a research note on Tuesday, July 29th. Finally, analysts at MLV & Co
cut their price target on shares of Galectin Therapeutics from $27.00 to $15.00 in a research note on Tuesday, July 29th. They now have a “buy” rating on the stock.
Galectin Therapeutics Inc (NASDAQ:GALT) is a development-stage company engaged in drug development to create new therapies for cancer and fibrotic disease.
Receive News & Ratings for Galectin Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.